Oseltamivir for influenza in pregnancy |
| |
Institution: | 1. National Institute of Science and Technology in Tropical Diseases, Brazil and Federal University of Bahia, Salvador, Brazil;2. Program of Post-graduation in Health Sciences, Federal University of Bahia, Salvador, Brazil;3. Telethon Kids Institute, The University of Western Australia, Subiaco, Western Australia, Australia;2. Division of Cardiovascular and Thoracic Surgery, Duke University Medical Center, Durham, North Carolina;3. Duke Children''s Pediatric and Congenital Heart Center, Duke Children''s Hospital, Durham, North Carolina |
| |
Abstract: | Pregnancy predisposes women to disproportionate morbidity and mortality from influenza infections. This is true for both seasonal epidemics as well as occasional pandemics. Inactivated yearly influenza vaccines are the best available method of disease prevention and are recommended for all pregnant women in any trimester of pregnancy and postpartum. Oseltamivir (Tamiflu®) is currently the first-line recommended and most commonly used pharmaceutical agent for influenza prophylaxis and treatment. Oseltamivir has been demonstrated to prevent disease among exposed individuals, as well as to shorten the duration of illness and lessen the likelihood of complications among those infected. The physiologic adaptations of pregnancy may alter the pharmacokinetics and pharmacodynamics of this important drug. Updated evidence regarding these potential alterations, current knowledge gaps, and future investigative directions is discussed. |
| |
Keywords: | Influenza Pregnancy Oseltamivir Pharmacology |
本文献已被 ScienceDirect 等数据库收录! |
|